KURA ONCOLOGY, INC. Contract Liability (Deferred Revenue)
KURA ONCOLOGY, INC. (KURA) had Contract Liability (Deferred Revenue) of $55.48 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2026-08-12
- 2026-06-30: Contract with Customer, Liability, Current $55.48M.
- 2026-03-31: Contract with Customer, Liability, Current $47.70M.
- 2025-12-31: Contract with Customer, Liability, Current $48.98M.
- 2025-09-30: Contract with Customer, Liability, Current $48.75M.
| Period end | Contract with Customer, Liability, Current |
|---|---|
| 2026-06-30 | $55.48M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $47.70M 10-Q · filed 2026-05-12 |
| 2025-12-31 | $48.98M 10-Q · filed 2026-08-12 |
| 2025-09-30 | $48.75M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $49.44M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $40.85M 10-Q · filed 2025-05-01 |
| 2024-12-31 | $24.27M 10-K · filed 2026-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |